Kamada Ltd Aktie News

Kamada Ltd. (NASDAQ:KMDA ) Q1 2024 Earnings Conference Call May 8, 2024 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors, LLC Amir London - Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel Operator Good morning, ladies and gentlemen, and welcome to the Kamada Limited First Quarter 2024 Earnings Conf...

REHOVOT, Israel and HOBOKEN, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for three months ended March 31, 2024.

REHOVOT, Israel and HOBOKEN, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter ended March 31, 2024, pri...

Kamada Ltd. (NASDAQ:KMDA) Q4 2023 Results Earnings Conference Call March 6, 2024 8:30 AM ET

REHOVOT, Israel, and HOBOKEN, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today issued a Letter to Shareholders from Amir London, Chief Executive Officer.

REHOVOT, Israel, and HOBOKEN, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced financial results for the three months and year ended December 31, 2023.

REHOVOT, Israel, and HOBOKEN, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd.

Kamada is a profitable specialty plasma company with a strong balance sheet and significant capital available for investment. The company has announced an expanded commercial agreement for its anti-rabies drug Kedrab including a minimum revenue guarantee for the next four years. The new deal significantly derisks the Kamada investment case by locking in growth for one of the company's largest r...